WO2004005476A3 - Nucleic acid compositions for stimulating immune responses - Google Patents

Nucleic acid compositions for stimulating immune responses Download PDF

Info

Publication number
WO2004005476A3
WO2004005476A3 PCT/US2003/021113 US0321113W WO2004005476A3 WO 2004005476 A3 WO2004005476 A3 WO 2004005476A3 US 0321113 W US0321113 W US 0321113W WO 2004005476 A3 WO2004005476 A3 WO 2004005476A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
immune responses
acid compositions
stimulating immune
stimulating
Prior art date
Application number
PCT/US2003/021113
Other languages
French (fr)
Other versions
WO2004005476A2 (en
Inventor
Arthur M Krieg
Original Assignee
Coley Pharm Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Group Inc filed Critical Coley Pharm Group Inc
Priority to JP2004519911A priority Critical patent/JP2005532067A/en
Priority to EP03763239A priority patent/EP1551221A4/en
Priority to AU2003247880A priority patent/AU2003247880B2/en
Priority to CN038208636A priority patent/CN1678188B/en
Priority to CA002494508A priority patent/CA2494508A1/en
Publication of WO2004005476A2 publication Critical patent/WO2004005476A2/en
Publication of WO2004005476A3 publication Critical patent/WO2004005476A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
PCT/US2003/021113 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses WO2004005476A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004519911A JP2005532067A (en) 2002-07-03 2003-07-03 Nucleic acid composition for stimulating immune response
EP03763239A EP1551221A4 (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses
AU2003247880A AU2003247880B2 (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses
CN038208636A CN1678188B (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses
CA002494508A CA2494508A1 (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US39419302P 2002-07-03 2002-07-03
US39409102P 2002-07-03 2002-07-03
US39416402P 2002-07-03 2002-07-03
US39388002P 2002-07-03 2002-07-03
US39409002P 2002-07-03 2002-07-03
US60/394,193 2002-07-03
US60/394,164 2002-07-03
US60/394,090 2002-07-03
US60/393,880 2002-07-03
US60/394,091 2002-07-03

Publications (2)

Publication Number Publication Date
WO2004005476A2 WO2004005476A2 (en) 2004-01-15
WO2004005476A3 true WO2004005476A3 (en) 2004-05-21

Family

ID=30119452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021113 WO2004005476A2 (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses

Country Status (7)

Country Link
EP (1) EP1551221A4 (en)
JP (2) JP2005532067A (en)
CN (1) CN1678188B (en)
AU (1) AU2003247880B2 (en)
CA (1) CA2494508A1 (en)
SG (1) SG167667A1 (en)
WO (1) WO2004005476A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2587633C2 (en) * 2011-05-26 2016-06-20 Интервет Интернэшнл Б.В. Immunostimulating oligodeoxynucleotides

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098491A2 (en) 2002-11-01 2004-11-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
MX2009003398A (en) * 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
ES2544484T3 (en) * 2007-05-18 2015-08-31 Adiutide Pharmaceuticals Gmbh Phosphate modified oligonucleotide analogues with immunostimulatory activity
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
JP5359883B2 (en) * 2007-11-28 2013-12-04 東レ株式会社 Hepatitis treatment or prevention
CN101559224B (en) * 2008-04-18 2012-07-11 北京生物制品研究所 Poliomyelitis vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
CN103517707A (en) * 2011-04-29 2014-01-15 西莱克塔生物科技公司 Controlled release of immunosuppressants from synthetic nanocarriers
PL2714908T3 (en) * 2011-05-26 2018-07-31 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
KR20220025909A (en) 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
CN108079290A (en) * 2013-05-14 2018-05-29 硕腾服务有限责任公司 Novel vaccines composition comprising immunostimulatory oligonucleotide
BR112017001470A2 (en) 2014-09-07 2018-02-20 Selecta Biosciences Inc methods and compositions for attenuating the immune responses of the gene therapy antiviral transfer vector
WO2016115500A1 (en) * 2015-01-16 2016-07-21 City Of Hope Cell penetrating antibodies
CA3031778A1 (en) * 2016-07-26 2018-02-01 Bayer Animal Health Gmbh Increased fertility in bovine species
CN110612122A (en) 2017-03-11 2019-12-24 西莱克塔生物科技公司 Methods and compositions related to combination therapy with anti-inflammatory agents and synthetic nanocarriers comprising immunosuppressants
CN113440609A (en) * 2020-03-27 2021-09-28 北京市农林科学院 Double-stranded RNA compound AUTP and application thereof in vaccine preparation
CN113493790A (en) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 CpG ODN with immunoregulation function and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2000067787A2 (en) * 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2001092565A2 (en) * 2000-04-06 2001-12-06 Epigenomics Ag Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
WO2002018632A2 (en) * 2000-09-01 2002-03-07 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078053B1 (en) * 1998-05-14 2005-09-28 Coley Pharmaceutical GmbH METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1077722T3 (en) * 1998-05-22 2006-11-27 Ottawa Health Research Inst Methods and products for the induction of mucosa immunity
EP1700603A3 (en) * 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Immunostimulatory nucleic acids
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
CN1604795B (en) * 2001-08-17 2010-05-26 科勒制药股份公司 Combination motif immune stimulatory oligonucleotides with improved activity
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
ATE544466T1 (en) * 2002-10-29 2012-02-15 Coley Pharm Group Inc USE OF CPG OLIGONUCLEOTIDES TO TREAT HEPATITIS C VIRUS INFECTION
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
EP1631687A2 (en) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2000067787A2 (en) * 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
WO2001092565A2 (en) * 2000-04-06 2001-12-06 Epigenomics Ag Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
WO2002018632A2 (en) * 2000-09-01 2002-03-07 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2587633C2 (en) * 2011-05-26 2016-06-20 Интервет Интернэшнл Б.В. Immunostimulating oligodeoxynucleotides

Also Published As

Publication number Publication date
CN1678188B (en) 2012-10-10
JP2009132737A (en) 2009-06-18
AU2003247880A1 (en) 2004-01-23
WO2004005476A2 (en) 2004-01-15
CA2494508A1 (en) 2004-01-15
CN1678188A (en) 2005-10-05
SG167667A1 (en) 2011-01-28
EP1551221A2 (en) 2005-07-13
AU2003247880B2 (en) 2010-09-02
JP2005532067A (en) 2005-10-27
EP1551221A4 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2004016805A3 (en) Immunostimulatory nucleic acids
WO2004030608A3 (en) Nanoemulsion vaccines
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
WO2008142509A3 (en) Class a oligonucleotides with immunostimulatory potency
WO1999051259A3 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
WO2004058179A3 (en) Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2006135434A3 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2003008623A3 (en) Methylation analysis using nicking agents
WO2005060709A3 (en) Methods of use of probiotic bifidobacteria for companion animals
AU2002317910A1 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2002242085A1 (en) Methods and compositions useful for stimulating an immune response
AU2002361559A1 (en) Anticancer vaccine and diganostic methods and reagents
AU2003225946A1 (en) Methods and compositions for vaccination against or involvingenterobacteriaceae bacteria
TNSN05052A1 (en) Immunostimulatory nucleic acids
WO2003030656A3 (en) Methods and compositions for promoting growth and innate immunity in young animals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004519911

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003247880

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2494508

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003763239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038208636

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500034

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2003763239

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1-2005-500019

Country of ref document: PH